IFNA1 and cancer: HMAs exert several immunological effects: (a) HMA-induced IFN signaling blocks proliferation and lowers the apoptotic threshold of cancer cells [92]; (b) low-dose treatment with HMAs promotes expression of genes that are deregulated in tumors allowing immune evasion (MHC class I, cancer testis antigens, IFN type 1 and 3, ISGs) [90–93]; (c) HMAs induce secretion of CXCL-9 and -10 with subsequent recruitment of lymphocytes to the tumor site and thus increase the immunological visibility of the tumor [95, 121].